FN1 and Myocardial fibrosis: These results concur with our present observations that Col-1a1 and Fn-1, which are pro-fibrotic factors, are suppressed by evogliptin (Figure 2) and the reduction of myocardial fibrosis by evogliptin (Figure 5), indicating that this DPP-4 inhibitor may have pleiotropic anti-fibrosis effects.